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ABSTRACT 
Objective: To develop and validate simple, sensitive, accurate and selective UPLC-MS/MS method for quantification of paromomycin (PARO) in 
mice plasma. 
Methods: Precipitation method was used for the extraction of plasma samples, an aliquot of 25 µl plasma samples was extracted using 10% 
perchloric acid in water. Chromatographic separation was performed using waters acquity ultra-performance liquid chromatography (UPLC) 
columns, BEH HILIC (50 mm× 2.1 mm, 1.7 µm) by a gradient mixture of acetonitrile and water (both containing 0.005% v/v trifluro acetic acid) as a 
mobile phase at the flow rate of 0.2 ml/min. The analyte was protonated in the positive electrospray ionization (ESI) interface and detected in 
multiple reactions monitoring (MRM) modes using the transition m/z 308.60-455.30. 
Results: The method had a short chromatographic run time of 3 min. Calibration curves were linear over wide ranges of 50.51-5019.22 ng/ml. The 
between and within-batch precision and accuracy of the method was determined by using 4 quality control samples, the highest % CV observed was 
11.06. The mean recovery values are 78.17, 101.17 and 92.58 at low, medium and high-quality control levels; respectively. 
Conclusion: It was concluded that the developed and validated UPLC-MS/MS method was rapid, sensitive, accurate, precise, linear, and specific. 
Therefore, this method can be used for quantification of PARO in mice plasma with various advantages over the reported methods. 
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Paromomycin (PARO), a broad spectrum aminoglycoside antibiotic 
first isolated in 1956 from the fermentation of streptomyces, shows 
activity against both gram-positive and gram-negative bacteria as 
well as some protozoa and cestodes [1-2]. PARO has been approved 
since 2007 in India as an effective, well tolerated and affordable 
treatment for visceral leishmaniasis (VL). Visceral Leishmaniasis 
(VL) is a tropical disease caused by protozoan parasites of the genus 
leishmania and it is transmitted by the bite of certain species of the 
sand fly. Also called Kala Azar, the disease is endemic in parts of 
north-eastern India, sub-Saharan Africa, parts of the Mediterranean, 
and South America [3-6]. The disease has a worldwide distribution 
in Asia, East Africa, South America and the Mediterranean regions. It 
kills 200 000 to 300 000 people a year in the Indian subcontinent 
alone and is also greatly debilitating to those who survive the 
infection [7]. Recently it is being developed for use against multi-
drug resistant strains of tuberculosis and for the treatment of 
intestinal cryptosporidiosis in AIDS patients [8-10].  
To date, there have been many preliminary studies and published 
data on the various quantitative analysis of PARO, which include 
capillary zone electrophoresis, capillary electrophoresis, reverse-
phase ion-pairing HPLC coupled with pulsed amperometric 
detection, LC-MS, the use of silver-coated gold nanoparticles as 
concentrating probes and matrices for surface-assisted laser 
desorption/ionization mass spectrometry, and gas-liquid 
chromatography. Aminoglycosides viz PARO can be pre-treated to 
oxidation and thereby detecting it directly using amperometry. Also, 
pulsed amperometric detection (PAD) which has wide linearity 
range and very low detection limits for aminoglycoside [11]. Like 
other aminoglycosides, PARO has no ultraviolet (UV) absorbing 
chromophores, and, therefore, the derivatization of the amino 
groups is required for quantification using HPLC analyzes equipped 
with UV detector. This method is time-consuming, tedious and needs 
large sample volume for quantification; so harvesting a large 
quantity of plasma from small animals viz mice is challenging. An 
HPLC method with fluorescence detection was also developed using 
derivatization technique (post-column) with ortho-phthalaldehyde 
(OPA) and 2-mercaptoethanol, this is an indirect method (unlike 
UPLC-MS/MS), time-consuming, required long run time and more 
efforts without improving sensitivity. Pre-column labelling with OPA 
is not used because of the low stability of the derivative. Because of 
the thermal instability of aminoglycosides, the analysis of 
aminoglycosides by gas chromatography equipped with tandem 
mass spectrometry (GC/MS) is difficult [12-14].  
Thus considering the limitations of the various existing methods 
described, the present study was performed with the aim and 
objective to develop and validate a simple, sensitive, accurate and 
rapid UPLC-MS/MS method for the determination of PARO in mice 
plasma. Till recently there were no reports or validated methods 
available predominantly with high sensitivity and short run time for 
the quantification of PARO in mice plasma samples. 
MATERIALS AND METHODS 
Chemicals and reagents 
Paromomycin sulfate, antipyrine and K2EDTA were obtained from 
Sigma-Aldrich (Bangalore, India). Acetonitrile, trifluoroacetic acid 
and perchloric acid, were obtained from Merck (Mumbai, India). All 
other chemicals used in this study were of analytical grade. 
Animal husbandry and handling 
All animal studies had the approval of the Institutional Animal Ethics 
Committee as per approval number FB-15-067-M-117 of SAI Life 
Sciences Ltd. (an AAALAC accredited facility) and were in 
accordance with the guidelines of the CPCSEA, Government of India. 
Animals were acclimatized in study rooms for at least three days 
prior to dosing. Mice were housed in polypropylene cages (3 animals 
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per cage, marked for identification) maintained in controlled 
environmental conditions (22±3 °C; 40-70% RH; 10-15 fresh air 
change cycles/h) with 12 h light and dark cycles. Animals were 
obtained from the In vivo Biosciences, Bangalore, India. Mice were 
given rodent pellet diet and UV treated filtered water ad libitum. 
Mice blood samples were collected from retro-orbital plexus using a 
sparse sampling design.  
Instrumentation 
Stock solution, calibration standards and quality control samples 
A standard stock solution of PARO and antipyrine were prepared 
with a final concentration of 6.20 mg/ml and 2.40 mg/ml, 
respectively. These solutions were stored at 2-8 °C until use. The 
analytical standard for PARO in acetonitrile over a concentration 
range of 50.51 ng/ml to 5019.22 ng/ml by serial dilution method 
and same concentration range for calibration curve were also 
prepared in blank mice plasma. Quality control (QC) samples at four 
different concentration levels (50.51, 252.22, 752.88 and 1003.85 
ng/ml) for PARO as LLOQ QC, low (LQC), medium (MQC) and high 
(HQC), respectively were prepared in three sets independent of the 
calibration standards. During analysis, these QC samples were 
spaced after every six to seven unknown samples.  
Sample preparation 
An aliquot of 25 µl study sample or spiked calibration standard/QCs was 
added to individual pre-labeled microcentrifuge tubes followed by 25 µl 
of IS prepared in water (antipyrine, 500 ng/ml) was added except for 
blank mice plasma, where 25 µl of water was added. Samples were 
vortexed, followed by 100 µl of 10% perchloric acid in water was added 
and samples were vortexed for another 5 min. After centrifugation of the 
samples at 4000 rpm for 10 min at 4 °C, the supernatant was collected 
and 5 µl was injected onto the UPLC–MS/MS system.  
Chromatographic condition 
A Waters AcquityTM UPLC (USA) consisting of flow control valve, 
vacuum degasser operated in a gradient mode to deliver the mobile 
phase at a flow rate of 0.2 ml/min. The chromatographic system 
consisted of BEH HILIC column (50 mm× 2.1 mm, 1.7 µm) (Waters, 
USA) and mobile phase consists of methanol (A), 2 mmol ammonium 
acetate buffer (B), (pH ~3.2 adjusted with 0.1% formic acid). A 
gradient UPLC method with 3 min run time was employed for 
analysis. The mobile phase comprised 0.005% v/v trifluoroacetic 
acid in water and acetonitrile, the flow rate was 0.2 ml/min. 
Separation was achieved using BEH HILIC column (1.7 µm, 2.1 mm x 
50 mm, 3/pkg), Waters (USA), maintained at 45 °C employing an 
injection volume of 5 µl for in vivo samples.  
Mass spectrometric condition 
Mass spectrometric detection was performed on AB SCIEX triple 
quadrupole LC/MS/MS mass spectrometer equipped with electron 
spray ionization (ESI) source, the multiple reaction monitoring 
(MRM) modes was used for data acquisition with analyst 1.6.2 
software. Peak integration and calibration were carried out by using 
Analyst 1.6.2 software. MS and MS/MS condition for pure standards 
of PARO and IS antipyrine were optimized by continuous infusion at 
5 µl/min using syringe pump.  
The transitions monitored were m/z 308.6 (m/z)>455.3 and 
189.4>104.0 for components PARO and IS antipyrine, respectively. 
All analyzes were carried out in positive ion ESI with spray voltage 
set at 5500 V. The heated ESI temperature was set 550 °C. Nitrogen 
Ion Source Gas GS1 and GS2 set at 30 and 60 psi, respectively. The 
collision assisted dissociation (CAD) was used at pressure 6 psi. 
Total run time for UPLC-MS/MS analysis was 3 min. 
Application to pharmacokinetic study 
The method was successfully applied to evaluate the plasma 
concentration versus time profile of PARO in mice plasma following 
intravenous administration at 15 mg/kg dose of PARO. The 
intravenous dose volume was 5 ml/kg and dosing was performed 
using sterile 26 gauge needle via the tail vein. The formulation was 
prepared freshly on the day of dosing. Studies were performed in 
healthy male BALB/c mice (30-40 g). A sparse sampling design was 
used (n=3 per time point).  
Approximately, 60 µl of blood samples was collected (K2EDTA 
anticoagulant, 20 μl of K2EDTA solution/ml of blood, 200 mmol) at 
0.25, 0.5, 1, 4, 8 and 24 h postdose. Plasma samples were separated 




Fig. 1: Representative chromatograms of mice blank plasma using PARO and antipyrine LC/MS/MS method 
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Fig. 2: Representative chromatograms of PARO and antipyrine in mice plasma sample 
 
Pharmacokinetic parameters were calculated using non-compartmental 
analysis tool of WinNonlin® software (Version 6.3). The area under 
the concentration-time curve (AUClast and AUCinf) was calculated by 
linear trapezoidal rule. The peak concentration (Cmax) and time for 
the peak concentration (Tmax) were the observed values. The 
elimination rate constant value (kel) was obtained by linear 
regression of the log-linear terminal phase of the concentration-time 
profile using at least 3 non-zero declining concentrations in terminal 
phase with a correlation coefficient of>0.8. The terminal half-life 
value (T1/2) was calculated using the equation 0.693/kel. 
RESULTS AND DISCUSSION 
Mass spectrometry 
In order to find most, sensitive ionization mode for the components 
studied, ESI positive ion mode and ESI negative ion mode were 
tested with the various combination of mobile phase, i.e., methanol, 
acetonitrile and water/ammonium acetate buffer (2 mmol)/formic 
acid (0.1%) in positive and negative ionization mode. It was 
observed that the signal intensity for [M+H]+ ions in ESI positive ion 
mode were 3-10-fold higher for PARO using acetonitrile: 
trifluoroacetic acid in water (0.005% v/v), versus experiments run 
with ESI negative ion mode. The protonated molecular ion of 
[M+H]+, m/z 308.6 were obtained for PARO. No significant solvent 
adduct ions or fragment ions were observed in the full scan spectra 
of PARO and antipyrine (IS). Thus, it was decided to utilize positive 
ion mode for detection and quantification of [M+H]+ ions and 
representative chromatogram showed in the fig. 1 and 2. 
Liquid chromatography  
Acetonitrile rather than methanol was chosen as an organic modifier 
because of its better peak shape. A gradient UPLC method with a 3 
min run time was employed for analysis. The mobile phase 
comprised of 0.005% v/v trifluoroacetic acid in water and 
acetonitrile and the flow rate was 0.2 ml/min. Separation was 
achieved using BEH HILI column (1.7 µm, 2.1 mm x 50 mm, 3/pkg), 
Waters, USA) maintained at 45 °C employing an injection volume of 
5 µl for in vivo plasma samples. 
Optimization of UPLC–MS/MS condition 
Final MRM transitions were selected on the basis of the signal to 
noise ratio (S/N) ratio with on-column injection analysis. Curtain 
gas, collision gas induced dissociation, ion spray voltage, and 
temperature were set to 25.00 psi, 6 psi, 5500.00 v and 550.00 C, 
respectively. Positive-ion electron spray ionization mode was used 
and MRM transitions of 308.60/455.30 for PARO and 189.40/104.00 
for antipyrine were monitored.  
Sample clean-up 
The next step was to develop the simple and efficient sample clean 
up devoid of matrix effect and interference from endogenous plasma 
components for estimation of PARO in mice plasma. Precipitation 
method was tried with acetonitrile; liquid–liquid extraction (LLE) 
using ether and different combinations of hexane and ethyl acetate 
(80–20%, v/v), n-hexane and isopropyl alcohol (2–5%, v/v) was also 
tried but none of these was found suitable to give good and 
consistent recovery for PARO. Finally, precipitation method was tried 
with 10% perchloric acid in water and found suitable to give optimum 
recovery for PARO and IS. Since PARO is highly polar in nature and not 
extracted in acetonitrile and methanol by protein precipitation 
method. Hence 10% perchloric acid in water was used. For 
determination of matrix effect, control drug-free plasma was extracted 
using the described method and drug was added in extracted 
supernatant. Matrix effect was determined by comparing the analytical 
response of these samples with that of standard solutions. 
Method validation 
Accuracy, precision, selectivity, sensitivity, linearity and stability were 
measured and used as the parameter to assess the assay performance. 
LC–MS/MS analysis of the blank plasma samples showed no 
interference with the quantification of PARO and the IS (antipyrine). 
The specificity of the method was established with pooled and 
individual plasma samples from six different sources. The retention 
times of PARO and the IS showed less variability with a percent 
coefficient of variance (%CV) well within acceptable limits of 5%. 
Limit of detection (LOD) and quantification (LOQ) 
Two criteria were used to define LOQ, i.e., (1) the analytical response 
at LOQ must be five times the baseline noise and (2) the analytical 
response at LOQ can be detected with sufficient accuracy (80-120%) 
and precision (20%). LOD is defined as the lowest concentration of 
the analyte at which the signal is larger than three times the baseline 
noise. The measured LOQ and LOD values were 50.00 and 10.00 
arbitrary units for PARO. The limit of quantification (LOQ) was set at 
50.51 ng/ml. These results well met the requirements of 
quantifications of all analytes in plasma.  
Linearity 
The peak area ratios of analyte to IS in mice plasma were linear over 
the concentration range 50.51 to 5019.22 ng/ml for PARO. The 
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calibration model was selected based on the analysis of the data by 
linear regression with and without intercepts (y = mx+c and y = mx) 
and weighting factors (1/x, 1/x2 and 1/log x). The best fit for the 
calibration curve could be achieved by a linear equation of y = mx+c 
and a 1/x2 weighting factor for all components. The correlation 
coefficients (R2) for all components were above 0.9900 over the 
concentration range used.  
Precision and accuracy 
The intra-day precision (expressed by percent coefficient of 
variation i. e CV% of replicate analyzes) was estimated on the four 
quality control levels and the within-batch precision on the ten 
calibration standard levels. Table 1 shows the results obtained for 
the within a batch and between batch precision for PARO. The 
precision for all these analytes under investigation was not exceeded 
15% at any of the concentrations studied and well met the 
requirements of validation. 
Recovery 
The extraction recovery of PARO from mice plasma was estimated at 
their respective low, medium and high QC levels. Plasma samples (in 
six replicates) containing PARO at QC concentration level was also 
spiked with respective internal standards. The results of absolute 
recoveries ranged from 78.17 to 101.17% are indicated in table 2. 
 







Mean measured concentration (ng/ml); % mean 
accuracy;  % mean CV 
Mean measured concentration (ng/ml); %  mean 
accuracy; % mean CV 
PAR
O 
50.51 55.55; 109.99; 4.88 54.44; 107.79; 4.55 
252.22 239.96; 95.17; 8.26 228.54; 90.61; 4.17 
752.88 849.81; 112.87; 2.64 701.32; 93.15; 11.06 
1003.85 1084.52; 108.04; 7.51 984.20; 98.04; 6.16 
 Data of n=6 replicates 
 
Table 2: Extraction recovery of PARO in BALB/c mice plasma 
Analyte Concentration (ng/ml) % mean recovery  % mean CV  
PARO 252.22 78.17 12.82 
752.88 101.17 
1003.85 92.58 
Data of n=6 replicates 
 
Stability  
QC samples were subjected to short term and long term storage 
condition (-70 °C), freeze-thaw stability, auto-sampler stability and 
bench-top stability studies. All stability studies were carried out at 
two concentration levels (low and high QC) in six replicates. The 
bench top stability was studied for low and high QC samples kept at 
room temperature (25 °C) for 6 h. Freeze-thaw stability of low and 
high QC samples was evaluated after 3 freeze-thaw cycles. The auto-
sampler stability was studied for low and high QC samples stored at 
auto-sampler at 10 °C for 24 h.  
The freezer storage stability of the drug in plasma was determined 
by comparing the low and high QC samples stored for 30 d at-70 °C. 
The results indicated that each analyte had an acceptable stability 
under the conditions, as shown in table 3. 
  




Bench top stabilitya Auto-sampler stabilityb Freeze-thaw stabilityc 30 d storage stabilityd 
% accuracy; %CV % accuracy; %CV % accuracy; %CV % accuracy; %CV 
PARO 252.22 102.30; 5.30 98.36; 6.80 95.36; 3.65 107.21; 5.66 
1003.85 98.50; 6.44 96.50; 7.12 105.20; 5.21 98.36; 8.32 
Data of n=6 replicates; aExposed at ambient temperature (25 °C) for 6 h; bKept at autosampler temperature (10 °C) for 24 h; cAfter three freeze-thaw 
cycles; dStored at-70 °C 
 
Sample dilution 
To demonstrate the ability to dilute and analyze samples containing 
PARO at the concentration above the assay upper limit of 
quantification, a set of plasma samples was prepared to contain 
PARO at a concentration of 9034.60 ng/ml, and placed in a-70 °C 
freezer overnight prior to analysis. After thawing, the certain aliquot 
was diluted either with 2 and 10 times mice plasma and analyzed 
respectively. The results of this experiment indicated that the 
dilution integrity of all the plasma samples was found to be less than 
15% of their respective nominal concentrations.  
Advantages of present method 
The aim of present investigation was to develop and validate a 
simple LC-MS/MS method using gradient mode with sufficient 
accuracy and precision for PARO and its subsequent use in 
pharmacokinetic studies in mice. The present method involves 
simple precipitation procedure with good sensitivity and a gradient 
reverse-phase UPLC analysis for PARO. This method is specific for 
PARO with no interference and with good linearity, accuracy, and 
precision. This method involves only 25 µl of plasma and in our LLE 
extraction procedure, we achieved a high level of extraction 
efficiency for PARO. This makes the assay highly reproducible and 
allows us to lower the limit of quantification. Furthermore, this one-
step precipitation extraction procedure uses simple, low cost and 
short run time. The chromatographic conditions of this method were 
optimized for a short 3 min run time in UPLC-MS/MS. 
Application to pharmacokinetic study 
The method described above was successfully applied to a 
pharmacokinetics evaluation of PARO, in which plasma 
concentrations were determined up to 24 h, following intravenous 
administration at 15 mg/kg dose of PARO in male BALB/c mice. The 
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plasma concentration time profile of PARO is shown in fig. 3 and 
mean pharmacokinetic parameters are presented in table 4. The 
compound was well distributed with a steady-state volume of 
distribution that was 2.62-fold higher than the total body water (0.7 
l/kg). It showed a low intravenous plasma clearance with an 
elimination half-life of 2.60 h. 
  
 
Fig. 3: Mean plasma concentration vs. time following a single dose intravenous administration of PARO in male BALB/c mice 
 
Table 4: Mean pharmacokinetic parameters following single intravenous administration of PARO in male BALB/c mice 
Analyte C0 (ng/ml) AUC(0-t) (h*ng/ml)  AUC(0-inf) (h*ng/ml)  T1/2 (h) CL (ml/min/kg)  Vss (l/kg) 
PARO 16267.49 30597.46 30626.77 2.60 8.16 1.84 
Data of n=3 replicates; AUC: area under the concentration-time curve; C0,-back extrapolated plasma concentrations; T1/2: half-life; CL: plasma 
clearance; Vss: volume of distribution at steady state. 
 
CONCLUSION 
The UPLC-MS/MS bioanalytical method for determination PARO was 
developed and validated in mice plasma. The method was sensitive 
enough to detect low concentration of 50.51 ng/ml for PARO. 
Recovery of PARO from spiked control samples were >78% by using 
convenient and rapid precipitation method using perchloric acid in 
water. Intra and inter-day accuracy and precision of the validated 
method were within the acceptable limits of <20 at LLOQ and <15% 
at low, medium and high concentrations. The method was 
successfully applied to generate the pharmacokinetic evaluation of 
PARO in mice plasma following intravenous administration. 
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